New biologic GB-0895 enters first human safety trial for asthma and COPD

NCT ID NCT07116889

Ongoing Disease control Sponsor: Generate Biomedicines Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-stage study is testing an experimental drug called GB-0895 in 156 adults with mild-to-moderate asthma or COPD. The main goal is to check if the drug is safe and how the body processes it. Participants receive either the drug or a placebo as an injection under the skin. This is a first-in-human trial, so there is no proof yet that GB-0895 improves breathing or disease control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GB-0895 (an experimental biologic drug given as an injection under the skin)
What this could lead to: If safe and effective, GB-0895 could become a new treatment option to help control asthma or COPD symptoms.
What could go wrong: This is a very early Phase 1 trial focused on safety, not on whether the drug works. It involves only 156 people, so results may not apply to everyone. Side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma chronic obstructive pulmonary disease COPD, severe early onset

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASTHMA COPD (CHRONIC OBSTRUCTIVE PULMONARY DISEASE)

Contacts and locations

Locations

Alcanza

DeLand, Florida, 32720, United States
Charite Research Organization GmbH

Berlin, Germany
DM Clinical Research

Tomball, Texas, 77375, United States
Fraunhofer Institut fur Toxikologie and Experimentelle Medizin (ITEM)

Hanover, Germany
Hammersmith Medicines Research

London, United Kingdom
IKF Pneumologie

Frankfurt, Germany
Medicines Evaluation Unit (MEU)

Manchester, United Kingdom
Miami Research Institute of South Florida

Miami, Florida, 33173, United States
Nucleus Network

Saint Paul, Minnesota, 55114, United States
Omega Research

Orlando, Florida, 32808, United States
Queen Anne Street Medical Center

London, United Kingdom
Simbec-Orion Clinical Development

Merthyr Tydfil, United Kingdom
Southeastern Research Center

Winston-Salem, North Carolina, 27103, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.